Braganza Georgina, Chaudhuri Rekha, Thomson Neil C
Department of Respiratory Medicine, Division of Immunology, Infection & Inflammation, University of Glasgow, Glasgow, UK.
Ther Adv Respir Dis. 2008 Apr;2(2):95-107. doi: 10.1177/1753465808089697.
The high prevalence of cigarette smoking in patients with respiratory disease puts them at risk of developing clinically important drug interactions. Cigarette smoking reduces the therapeutic response to certain drugs such as theophyllines through the induction of hepatic cytochrome P450 isoenzymes. Smokers with asthma and patients with COPD have reduced sensitivity to corticosteroids, possibly due to non-eosinophilic airway inflammation, altered glucocorticoid receptor activity or reduced histone deacetylase activity. Although all smokers should be encouraged to stop smoking, there is limited information on the influence of smoking cessation on the therapeutic and anti-inflammatory effects of a number of the drugs used in the treatment of respiratory disease.
呼吸系统疾病患者中吸烟率很高，这使他们面临发生具有临床重要性药物相互作用的风险。吸烟通过诱导肝细胞色素P450同工酶降低对某些药物（如茶碱类）的治疗反应。哮喘吸烟者和慢性阻塞性肺疾病（COPD）患者对皮质类固醇的敏感性降低，这可能是由于非嗜酸性气道炎症、糖皮质激素受体活性改变或组蛋白脱乙酰酶活性降低所致。尽管应鼓励所有吸烟者戒烟，但关于戒烟对多种用于治疗呼吸系统疾病药物的治疗和抗炎作用的影响，相关信息有限。
